Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: The regulation of lymph node cell populations and cytokine production

Inflammation Research

Volumn 45, Issue 4, 1996, Pages 159-165

  Haynes, D R ^a   Gadd, S J ^b   Whitehouse, M W ^c   Mayrhofer, G ^a   Vernon Roberts, B ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Arthritis; Cyclosporin; Cytokines and lymphocytes; Lobenzarit

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; LOBENZARIT; TUMOR NECROSIS FACTOR;

ADJUVANT DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL TYPE; CHRONIC INFLAMMATION; CONTROLLED STUDY; IMMUNOFLUORESCENCE TEST; LYMPH NODE CELL; MALE; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTHRANILIC ACIDS; ANTIGENS, CD4; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; B-LYMPHOCYTES; CACHEXIA; CELL DIVISION; CYCLOSPORINE; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; LYMPH NODES; MALE; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029866035     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02285155     Document Type: Article

References (44)

1. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthr Rheum 1993;36:1681-90.
2. Haynes DR, Garrett IR, Vernon-Roberts B. Effect of gold salt treatment on receptor binding activity of monocytes and macrophages isolated from rats with adjuvant arthritis. Rheumatol Int 1988;8:159-64.
3. Connolly KM, Stecher VJ, Danis E, Purden DJ, LaBrie T. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying drugs. Agents Actions 1988;25:94-105.
4. Dougados M, Torley H. Efficacy of cyclosporin A in rheumatoid arthritis: worldwide experience. Br J Rheumatol. 1993;(1 Suppl)32:57-9.
5. Sany J. Immunological treatment of rheumatoid arthritis. Clin Exp Rheumatol 1990;(5 Suppl)8:81-8.
6. Clerici M, Shearer GM. Differential sensitivity of human T helper cell pathways by in vitro exposure to cyclosporin A. J Immunol 1990;144:2480-5.
7. Katagiri K, Nakano T, Sugawara Y, Ichikawa Y, Yoshida T. CCA (disodium 4-chloro-2,2′-iminodibenzoate) inhibits the progression of human T cell proliferation triggered by PHA. Clin Immunol Immunopathol 1990;56:384-92.
8. Varey A, Champion BR, Cooke A, Cyclosporin affects the function of antigen-presenting cells. Immunol 1986;57;111-4.
9. Takeuchi T, Koide J, Hosono O, Takano M, Abe T. CCA [N-(2-carboxyphenyl)-4-chloroanthranilic acid sodium salt], a newly developed immunomodulating drug, suppresses T-cell activation by acting on macrophages. Inflammation 1989; 13:124-35.
10. Klaus GGB. Cyclosporin-sensitive and cyclosporin-insensitive modes of B cell stimulation. Transplantation 1988;46:11S-4.
11. Hirohata S, Shinohara S, Inuoue T, Miyamoto T, Lipsky PE. Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug. Arthr Rheum 1992;35:168-74.
12. Takeda Y, Urakawa K, Sakamoto A, Nakano T, Sugawara Y, Ohsugi Y, et al. Lobenzarit disodium (CCA) inhibits in vitro immunoglobulin production via direct interaction with B lymphocytes. Chem Pharm Bull Tokyo 1992;40:177-181.
13. Del-Pozo E, Graeber M, Elford P, Payne T. Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A. Arthr Rheum 1990;33:247-52.
14. Whitehouse MW, Rainsford KD, Taylor RM, Vernon-Roberts B. Zinc monoglycerate: A slow release source of zinc with antiarthritic activity in rats. Agents Actions 1990;31:47-58.
15. Imaizumi K, Hinoue H, Ueno M, Takata I, Sato T, Minato Y, et al. Pathological evaluation of anti-rheumatic drugs on type II collagen-induced arthritis in DBA/1J mouse. Jikken Dobutsu 1991;40:95-9.
16. Whitehouse MW, Vernon-Roberts B. Prevention of rat polyarthritis induced with mycobacterial or avridine adjuvants. XVIIth ILAR Congress of Rheumatology 1989;13.
17. Haynes DR, Garrett IR, Whitehouse MW, Vernon-Roberts B. Do gold drugs inhibit interleukin-1? Evidence from an in vitro lymphocyte activating factor assay. J Rheumatol 1988;15:775-8.
18. 3. Immunol 1992;76:251-7
19. Bazin H, Xhurdebise LM, Burtonboy G, LeBaq AM, De Clercq L, Cormont F. Rat monoclonal antibodies. i. rapid purification from in vitro culture supernatants. J Immunol Meth 1984;66:261-9.
20. Hunig T, Wallny H-J, Hartley JK, Lawetzky A, Tiefenthaler G. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation: different reactivity with subsets of immature and mature T lymphocytes. J Exp Med 1989;169:73-86.
21. Fukumoto T, McMaster WR, Williams AF. Mouse monoclonal antibodies against rat major histocompatibility antigens. Two Ia antigens and class I antigens in rat thymus. Eur J Immunol 1982;12:237-43.
22. Dallman MJ, Mason DW, Webb M. The roles of host and donor cells in the rejection of skin allografts by T cell-deprived rats injected with syngenetic T cells. Eur J Immunol 1982; 12:511-18.
23. Mason DW, Brideau RJ, McMaster WR, Webb M, White RAH, Williams AF. Monoclonal antibodies that define T-lymphocyte subsets in the rat. In: Kennett RH, McKearn TJ, Bechtol KB, editors. Monoclonal antibodies. London: Plenum Publishing Corp., 1980:251-301.
24. Gadd SJ, Ashman LK. Binding of mouse monoclonal antibodies to human leukemia cells via the Fc receptor: a possible source of 'false positive' reactions in specificity. Clin Exp Immunol 1983;54:811-8.
25. Snedecor GW, Cochran WG, editors. Statistical Methods. 8th ed. Ames, Iowa: Iowa State University Press, 1989.
26. Madhok R, Capell HA. Cyclosporin A in Rheumatoid Arthritis: Results at 30 months. Transplant Proc 1988;20(4 Suppl):248-52.
27. Cohen IR, Holoshitz J, Van Eden, Frenkel A. T lymphocyte clones illuminate pathogenesis and affect therapy of experimental arthritis. Arthr Rheum 1985;28:841-5.
28. Larsson P, Holmdahl R, Denker L, Klareskog L. In vivo treatment with W3/13 (anti-pan T) but not with OX8 (antisuppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. Immunol 1985; 56:383-91.
29. Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982;128:355-91.
30. Groeniwegen G, Buurman WS, Jeanhomme GMA, Van Der Linden CJ. Effect of cyclosporin on MHC class II antigen expression on arterial and venous endothelium in vitro. Transplantation 1985;40:21-5.
31. Kunkl A, Klauss GGB. Selective effects of cyclosporin A on functional B cell subsets. J Immunol 1980;125:2526-31.
32. White DJD, Plumb A, Calne RY. The immune status of transplantation recipients immunosuppressed with cyclosporin A Transplant Proc 1980;13:1666-8.
33. Van Den Broek MF, Van Den Langerit LG, Van Bruggen MC, Billingham MEJ, Van den Berg WB. Treatment of rats with monoclonal anti-CD4 induces long term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1992;22: 57-61.
34. Mosmann TR, Coffman RL. TH1 and TH2: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
35. Andersson J, Nagy S, Groth C-G, Andersson U. Effects of FK 506 and cyclosporin A on cytokine production studies in vitro at a single-cell level. Immunol 1992;75:136-42.
36. Theisen-Popp P, Pape H, Müller-Peddinghaus R. Interleukin-6 in adjuvant arthritis of rats and its pharmacological modulation. Int J Immunopharmacol 1992;14:565-71.
37. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993;5:298-304.
38. Brauer R, Kette H, Henzgen S, Thoss K. The influence of cyclosporin A on cytokine levels in synovial fluid and serum in rats with antigen induced arthritis. Agents Actions 1994; 41:96-8.
39. Weinblatt M, Helfgott S, Coblyn J, Spragg J, Uedelhoven WM, Tumel S, et al. The effects of cyclosporin A on eicosanoid excretion in patients with rheumatoid arthritis. Arthr Rheum 1991;34:481-5.
40. 2 of TNFα and IL-1 production by human monocytes. Immunol 1989;66:374-83.
41. Reem GH, Cook LA, Vilcek J. Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 1983;222:63-65.
42. Hirohata S. Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit. Clin Exp Rheumatol 1992;10:357-63.
43. Okamoto M, Sasano M, Goto M, Nishioka K, Nakamura K, Yokohari R. Suppressive effect of anti-rheumatic drugs on interleukin-1 beta release from human peripheral blood monocytes. Int J Immunopharmacol 1991;13:39-43.
44. Kawakami A, Eguchi K, Ueki Y, Migita K, Ida H, Nakao H, et al. Effects of lobenzarit disodium on human endothelial cells. Lobenzarit disodium inhibits proliferative response, HLA-DR antigen expression, and T cell adherence toward endothelial cells. Arthr Rheum 1991;34:296-303.